Who We Are
Who We Are
Offering Hope for a Single Curative Treatment
Novadip is committed to changing lives by providing innovative regenerative medicine solutions for patients with limited or no effective treatment options. Our team is focused on accelerated healing and single curative treatments for large bone defects, bone non-union and spine fusion.
Our Focus Is To Innovate To Improve Lives
Our focus and purpose are to develop a new class of regenerative tissue products to accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment. We’re driven by our passion to restore mobility, avoid amputations, and improve quality of life so patients can get back to living life.
Our History and Path
Novadip was founded in 2013 as a spin-off company from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder, Dr. Denis Dufrane. The basis of Dr. Dufrane’s research surrounded the creation of a unique 3M3 tissue regeneration platform, leveraging adipose-derived stem cells within a three-dimensional extracellular matrix. This technology aids in our mission to provide innovative solutions for patients with limited to no effective treatment options. Novadip’s growing team of 45 experts has published 9 manuscripts in peer-reviewed journals, created 15 procedures for bone reconstruction and generated 7 implantations for skin regeneration using early versions of the 3M3 technology. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.
Novadip is committed to advancing our 3M3 tissue regeneration platform to accelerate healing through single treatment cures.
Our Dedicated Team
Novadip’s highly experienced management team has a deep knowledge of science, regulation and development pathways, as well as a proven track record in significant fundraising for regenerative medicine companies.